Clinical Outcomes of Chimeric Antigen Receptor T-cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in 38 Patients with Refractory/relapsed Primary or Secondary Central Nervous System Lymphoma

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Nov 11

PMID 39527142

Authors

Jiaying Wu

Wanying Liu

Yang Cao

Yang Yang

Zhen Shang

Mi Zhou

Yicheng Zhang

Fankai Meng

Xiaojian Zhu

Yi Xiao

Affiliations

Soon will be listed here.

Abstract

Background: Several reports have indicated that chimeric antigen receptor (CAR) T-cell therapy following autologous hematopoietic stem cell transplantation (ASCT) is a promising strategy for refractory/relapsed (r/r) central nervous system lymphoma (CNSL), but the number of reported cases is limited.

Methods: The cohort in this retrospective study consisted of 38 patients with r/r CNSL who received CAR T-cell therapy following ASCT at our center between January 2019 and April 2024. Group comparisons of continuous variables were tested using the unpaired Student's t-test or the Mann-Whitney U-test, while categorical variables were analyzed using Fisher's exact test. The Kaplan-Meier method was employed to estimate survival curves, and group comparisons were performed using the log-rank test.

Results: The cohort comprised 38 patients with r/r CNSL, all of whom had active CNS involvement. After therapy, the best overall response rate (ORR) of all patients was 78.9%. Subgroup analysis found that a lower ORR was observed in patients with lactate dehydrogenase levels above the upper limit of normal (60.0% vs. 91.3%, P = 0.039). With a median follow-up of 37.5 months, the estimated 1-year overall survival (OS) and progression-free survival (PFS) rates were 72.8% and 57.4%, respectively. The risk factors associated with PFS was no response to current therapy (adjusted hazard ratio: 22.87, P < 0.001). The incidence rates of severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome were both 13.2%. Among the 25 patients with secondary CNSL (SCNSL), the best ORRs were 91.7% for those with CNS lesions only and 61.5% for those with CNS and systemic lesions (P = 0.160), while the estimated 1-year PFS rates were 83.3% and 38.5%, respectively (P = 0.030).

Conclusions: CAR T-cell therapy following ASCT shows promising efficacy for r/r CNSL patients. Besides, SCNSL patients with CNS and systemic lesions have inferior treatment efficacy compared to those with CNS lesions only.

References

Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek A . Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis. Am J Hematol. 2024; 99(8):1624-1627. DOI: 10.1002/ajh.27354. View

Rejeski K, Jain M, Shah N, Perales M, Subklewe M . Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024; 11(6):e459-e470. DOI: 10.1016/S2352-3026(24)00077-2. View

Wei J, Xiao M, Mao Z, Wang N, Cao Y, Xiao Y . Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. Signal Transduct Target Ther. 2022; 7(1):101. PMC: 8995369. DOI: 10.1038/s41392-022-00924-0. View

Wu J, Meng F, Cao Y, Zhang Y, Zhu X, Wang N . Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer J. 2021; 11(7):131. PMC: 8282870. DOI: 10.1038/s41408-021-00523-2. View

Zayac A, Evens A, Danilov A, Smith S, Jagadeesh D, Leslie L . Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021; 106(7):1932-1942. PMC: 8252937. DOI: 10.3324/haematol.2020.270876. View

Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R . CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network. Am J Hematol. 2024; 99(7):1240-1249. DOI: 10.1002/ajh.27316. View

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molucon-Chabrot C . Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC).... Ann Oncol. 2019; 30(4):621-628. DOI: 10.1093/annonc/mdz032. View

Wang T, Gao L, Wang Y, Zhu W, Xu L, Wang Y . Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma. Immunotherapy. 2020; 12(13):997-1006. PMC: 7546158. DOI: 10.2217/imt-2020-0075. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

10.

Cordeiro A, Bezerra E, Hirayama A, Hill J, Wu Q, Voutsinas J . Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transplant. 2019; 26(1):26-33. PMC: 6953906. DOI: 10.1016/j.bbmt.2019.08.003. View

11.

Lv L, Wu Y, Shi H, Sun X, Deng Z, Huo H . Efficacy and safety of chimeric antigen receptor T-cells treatment in central nervous system lymphoma: a PRISMA-compliant single-arm meta-analysis. Cancer Immunol Immunother. 2022; 72(1):211-221. PMC: 10991213. DOI: 10.1007/s00262-022-03246-w. View

12.

Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis B, Bartlett N . NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023; 21(11):1118-1131. DOI: 10.6004/jnccn.2023.0057. View

13.

Rejeski K, Subklewe M, Locke F . Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology Am Soc Hematol Educ Program. 2023; 2023(1):198-208. PMC: 10727074. DOI: 10.1182/hematology.2023000472. View

14.

Abrey L, Batchelor T, Ferreri A, Gospodarowicz M, Pulczynski E, Zucca E . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23(22):5034-43. DOI: 10.1200/JCO.2005.13.524. View

15.

Orellana-Noia V, Reed D, McCook A, Sen J, Barlow C, Malecek M . Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2021; 139(3):413-423. PMC: 8777199. DOI: 10.1182/blood.2021012888. View

16.

Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P . Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877. DOI: 10.1182/blood.2023020578. View

17.

Orellana-Noia V, Abousaud A . Secondary Central Nervous System Lymphoma: Updates in Treatment and Prophylaxis Strategies. Curr Treat Options Oncol. 2022; 23(10):1443-1456. DOI: 10.1007/s11864-022-01017-4. View

18.

Cao Y, Xiao Y, Wang N, Wang G, Huang L, Hong Z . CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2021; 27(11):910.e1-910.e11. DOI: 10.1016/j.jtct.2021.08.012. View

19.

Xue F, Zheng P, Liu R, Feng S, Guo Y, Shi H . The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. J Oncol. 2022; 2022:2900310. PMC: 9726247. DOI: 10.1155/2022/2900310. View

20.

Yu Q, Zhang X, Wang N, Li C, Zhang Y, Zhou J . Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed/refractory aggressive B-cell lymphoma. Radiother Oncol. 2022; 177:53-60. DOI: 10.1016/j.radonc.2022.10.018. View